Clozapine‐related seizures
The DOI matches its Crossref record.
Abstract
Clozapine is an atypical antipsychotic drug with minimal extrapyramidal toxicity recently approved by the Food and Drug Administration for hard-to-treat schizophrenic patients. We reviewed information on 1,418 patients treated with clozapine in the United States between 1972 and 1988. Forty-one of 1,418 (2.8%) patients had generalized tonic-clonic seizures during treatment with clozapine. Life-table analysis predicts a cumulative 10% risk of seizures after 3.8 years of treatment. Clozapine-related seizures appear to be dose-related. High-dose therapy (greater than or equal to 600 mg/day) was associated with a greater risk of seizures (4.4%) than medium (300 to 600 mg/day; 2.7%) or low doses (less than 300 mg/day; 1.0%). Also, rapid upward titration may increase seizure risk. Thirty-one of 41 patients were successfully continued on clozapine despite seizure occurrence, either with reduction of dose or addition of an antiepileptic medication. Recognition and treatment of clozapine-related seizures will become increasingly important as its use grows in the 1990s.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Alper, K., Schwartz, K. A., Kolts, R. L., & Khan, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.023 · Cited by 522
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.183 · Cited by 436
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Effects of Psychotropic Drugs on Seizure Threshold
Pisani, F., Oteri, G., Costa, C., Di Raimondo, G., & Di Perri, R. (2002) · Drug Safety · doi:10.2165/00002018-200225020-00004 · Cited by 352
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Pharmacokinetics and Pharmacodynamics of Clozapine
Jann, M. W., Grimsley, S. R., Gray, E. C., & Chang, W.-H. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324020-00005 · Cited by 257
Psychiatric comorbidities in epilepsy.
Josephson, C. B., & Jetté, N. (2017) · International Review of Psychiatry · doi:10.1080/09540261.2017.1302412 · Cited by 224
NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE
Chung, J. A., & Cummings, J. L. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70228-0 · Cited by 174
Clozapine as a Model for Antipsychotic Development
Nucifora, F. C., Mihaljevic, M., Lee, B. J., & Sawa, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0552-9 · Cited by 173
Detection and management of comorbidity in patients with schizophrenia
Green, A. I., Canuso, C. M., Brenner, M. J., & Wojcik, J. D. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00014-x · Cited by 159
The neuropsychiatry of adult-onset adrenoleukodystrophy
Rosebush, P. I., Garside, S., Levinson, A. J., & Mazurek, M. F. (1999) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.11.3.315 · Cited by 72
Metadata
- Authors
- Devinsky, O., Honigfeld, G., & Patin, J.
- Venue
- Neurology
- Published
- 1991-03
- Volume
- 41
- Issue
- 3
- Pages
- 369-369
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2162905199
- Cited by
- 322
- References
- 0
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.